Silexion Therapeutics Corp disclosed that three reporting persons—Intracoastal Capital, LLC, Mitchell P. Kopin and Daniel B. Asher—may each be deemed to beneficially own 244,771 ordinary shares, representing 9.99% of the class as of close of business on September 17, 2025. The filing explains these shares arise primarily from warrants issued under a Securities Purchase Agreement and notes multiple warrants include blocker provisions that limit exercise to prevent ownership above 9.99% (and 4.99% for one warrant). Voting and dispositive power over the 244,771 shares is reported as shared rather than sole.
Orca Capital AG reported beneficial ownership of 109,432 ordinary shares of Silexion Therapeutics Corp, representing 4.9% of the outstanding class based on 2,123,892 shares outstanding after the issuer's registered offering. The filing clarifies that the reporting person also holds warrants for 153,068 ordinary shares but cannot exercise them to the extent doing so would increase beneficial ownership above 4.99% (the "4.99% Blocker"). Orca states the securities were not acquired to change or influence control of the issuer and reports sole voting and dispositive power over the reported shares.